Skip to content
thestock.space

On 6 Nov 2026, Medico Remedies was priced at ₹17.99, or 10.8× trailing earnings, against an industry P/E of 28.7×, and the shares are 68% below their 52-week high. Sales and net profit grew 14% and 22% a year over 3 years; its ROCE of 25% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.25× equity. It is a small-cap company with a market cap of ₹149 Cr, ranked 103rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 63% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹18.40
Day high
₹18.47
Day low
₹17.81
Prev. close
₹18.45
Volume
2.1 L

Health check

3 good · 1 fair · 2 to check
  • ReturnsBehind

    −62.7% over a year, better than 0 of 7 peers.

  • Price tagCheaper

    P/E 10.8 vs industry 28.7.

  • GrowthStrong

    Sales +13.8%, profit +21.9% a year over 3 years.

  • ProfitabilityStrong

    ROCE 25.1% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.25× equity, interest covered 19.2×, Piotroski 5 of 9.

  • Red flags1 to check

    68% below its 52-week high.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹149 Cr, #103 of 154 in its industry by size.

Moves with the market

Beta 0.85 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹238 Cr · profit ₹14 Cr
Market cap
₹149 Cr
Small cap
P/E
10.8
Industry 28.7
Price to book
1.97
Peers 4.99
Dividend yield
0.00%
ROE
19.0%
Peers 14.7%
ROCE
25.1%
Peers 17.9%
Debt to equity
0.25
Debt ₹19 Cr
EPS (TTM)
₹1.67
Face value ₹2
OPM (TTM)
7.4%
Net margin 5.8%
Sales growth
+81.4%
Latest quarter vs a year ago
Profit growth
+38.5%
Latest quarter vs a year ago
Price to sales
0.63
EV/EBITDA 9.4

Strengths and risks

Strengths

  • Return on equity of 19.0%.
  • Return on capital employed of 25.1%.
  • Quarterly profit up 38.5% on a year ago.
  • Quarterly sales up 81.4% on a year ago.
  • P/E of 10.8 against an industry P/E of 28.7.

Risks to check

  • 68% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Medico Remedies

Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams;…

Headquarters
Mumbai
Employees
105
Sector
Healthcare
ISIN
INE630Y01024
Website
medicoremedies.com

Price range

52 weeks

₹17.81₹56.88

Today

₹17.81₹18.47
Avg volume (3M)
4.5 L
1-year return
minus 62.7%
From 52-week high
minus 68.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
MEDICOMedico Remedies17.99minus 2.49%14910.81.9725.1%19.0%3.7%13.8%21.9%0.00%minus 62.7%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
38.352.658.756.869.4
35.449.954.449.766.1
2.82.74.37.23.3
7.4%5.2%7.4%12.6%4.8%
0.71.70.72.91.2
0.30.20.40.90.4
0.80.70.80.80.7
2.43.53.88.33.3
25.3%26.1%25.1%29.6%24.6%
1.82.62.95.92.5
0.220.310.350.710.30

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+13.8%
Profit CAGR 3Y
+21.9%
EPS CAGR 3Y
+22.0%
ROE
19.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
138143149204
–+3.5%+3.7%+37.3%
126130134187
12.312.91517
8.9%9.0%10.1%8.3%
3.81.92.45.1
0.60.60.91
5.42.933.1
–0–0
10.111.313.518.1
28.3%26.9%25.3%27.4%
7.28.310.113.1
–+14.5%+21.7%+29.9%
0.871.001.221.58

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
16.616.616.616.6
27.235.845.958.9
9.88.114.719.3
33.835.842.658.7
87.496.2120153
21.921.421.723
0.10.10.52.6
–0.20.20
2.21.52.53.8
63.37394.9124
87.496.2120153

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8.22.44.95.9
−6.6−2.7−3.5−4.5
−1.8−0.5−0.5−0.6
−0.3−0.70.90.8
−6.6−2.5−3.2−4.5
1.6−01.71.4

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 0.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you